Výsledky vyhledávání - "Jeysen, Yogaratnam"

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

Autor: Joris, Vandenbossche, Jeysen, Yogaratnam, Vera, Hillewaert, Freya, Rasschaert, Willem, Talloen, Jeike, Biewenga, Jan, Snoeys, Thomas N, Kakuda, Martyn, Palmer, Julius, Nangosyah, Michael, Biermer

Publikováno v: Clinical Pharmacology in Drug Development. 11:1419-1429

The capsid assembly modulator JNJ-56136379 (bersacapavir) disrupts hepatitis B virus replication. It is metabolized via cytochrome P450 (CYP) 3A, but little is known about the drug-drug interactions of JNJ-56136379 when combined with drugs that inhib

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e46aeb60d5492b55a4cdaa1a03186527
https://doi.org/10.1002/cpdd.1164

Zobrazit plný text záznamu

Plný text ve formátu HTML

Alpha-kinase 1 (ALPK1) agonist DF-006 demonstrates potent efficacy in mouse and primary human hepatocyte (PHH) models of hepatitis B

Autor: Cong Xu, Jieqing Fan, Danyang Liu, Aimaier Tuerdi, Juanjuan Chen, Yuning Wei, Yanfang Pan, Huaixin Dang, Xiong Wei, Ashraf Siddig Yousif, Jeysen Yogaratnam, Qiong Zhou, Henri Lichenstein, Tian Xu

Publikováno v: Hepatology (Baltimore, Md.)REFERENCES.

In the treatment of chronic hepatitis B (CHB) infection, stimulation of innate immunity may lead to hepatitis B virus (HBV) cure. Alpha-kinase 1 (ALPK1) is a pattern recognition receptor (PRR) that activates the NF-κB pathway and stimulates innate i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fe11cb93ce42689dc2b611816c720a96
https://pubmed.ncbi.nlm.nih.gov/35699669

Zobrazit plný text záznamu

Pharmacokinetics, safety and tolerability of single- and multiple-ascending doses of JNJ-64530440, a novel hepatitis B virus capsid assembly modulator, in healthy volunteers

Autor: Sushmita Mukherjee Chanda, Christian Schwabe, E.J. Gane, Megha Patel, Oliver Lenz, Jan Snoeys, Jeysen Yogaratnam, Christopher Westland, Jennifer Vuong, Willem Talloen, Thomas N. Kakuda, Pieter Van Remoortere, John Fry

Publikováno v: Antiviral therapy. 26(1-2)

Background Pharmacokinetics and safety of JNJ-64530440, a hepatitis B virus capsid assembly modulator producing normal empty capsids (CAM-N), in healthy volunteers were evaluated. Methods This Phase I study (NCT03439488) was a double-blind, randomise

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7ca45ddd502f62d3dc189589442d5e
https://pubmed.ncbi.nlm.nih.gov/35485346

Zobrazit plný text záznamu

Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

Autor: Jan Martin Berke, Loeckie de Zwart, Willem Talloen, Maarten van den Boer, Jan Snoeys, Joris Vandenbossche, Jeysen Yogaratnam, W. Jessner, Jeike Biewenga

Publikováno v: Advances in Therapy. 36:2450-2462

Hepatitis B viral capsid assembly is an attractive target for new antiviral treatments. JNJ-56136379 (JNJ-6379) is a potent capsid assembly modulator in vitro with a dual mode of action. In Part 1 of this first-in-human study in healthy adults, the p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee338a6355add8de582946c10623603d
https://doi.org/10.1007/s12325-019-01017-1

Zobrazit plný text záznamu

JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Autor: Javier Crespo, Maria Buti, Christoph Sarrazin, Fabien Zoulim, Iurie Moscalu, Willem Talloen, Jeysen Yogaratnam, John Fry, Joris Vandenbossche, Juan Manuel Pascasio, Thomas Vanwolleghem, Oliver Lenz, Adrian Streinu-Cercel, Suzanne Bourgeois, Thierry Verbinnen, Umesh Shukla

Publikováno v: Gastroenterology, 159(2), 521-+. W.B. Saunders
Gastroenterology
Gastroenterology, WB Saunders, 2020, 159, pp.521-533.e9. ⟨10.1053/j.gastro.2020.04.036⟩

Background & Aims JNJ-56136379 (JNJ-6379), a capsid assembly modulator that blocks hepatitis B virus (HBV) replication, was well tolerated and demonstrated dose-proportional pharmacokinetics in healthy participants in part 1 of its first clinical tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d8e15501fdbb16f4db4269cc116b319
http://www.gastrojournal.org/article/S0016508520305199/pdf

Zobrazit plný text záznamu

Virology analysis of chronic hepatitis B virus-infected patients treated for 28 days with JNJ-56136379 monotherapy

Autor: Moana Hodari, David Blue, Jan Martin Berke, Joris Vandenbossche, Sandra De Meyer, Jeysen Yogaratnam, Thierry Verbinnen, Oliver Lenz, Umesh Shukla, Willem Talloen

Publikováno v: Journal of viral hepatitisREFERENCES. 27(11)

Four weeks of once-daily oral JNJ-56136379 (JNJ-6379; 25, 75, 150 or 250 mg), a class-N capsid assembly modulator (CAM-N), was well tolerated with potent antiviral activity in treatment-naive, chronic hepatitis B e antigen-positive and hepatitis B e

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbb72a2882652d59381a57ed917dd0c7
https://pubmed.ncbi.nlm.nih.gov/32579776

Zobrazit plný text záznamu

Phase I Study on Safety and Pharmacokinetics of a Novel Influenza Endonuclease Inhibitor, AL-794 (JNJ-64155806), following Single- and Multiple-Ascending doses in Healthy Adults

Autor: Jeysen Yogaratnam, John Fry, Toni Mitchell, Pieter Van Remoortere, Jennifer Rito, Thomas N. Kakuda, Malcolm Boyce, Kusum Gupta, Julian A. Symons, Sushmita Mukherjee Chanda

Publikováno v: Antiviral Therapy. 23:555-566

Background This double-blind, first-in-human Phase I study evaluated pharmacokinetics, safety and tolerability of AL-794 (prodrug of ALS-033719), a potent endonucle-ase inhibitor of influenza A and B in healthy volunteers. Methods Healthy adult volun

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01d50b661c1c6781b3f81b11244d7f58
https://doi.org/10.3851/imp3244

Zobrazit plný text záznamu

Antiviral Activity, Safety, and Pharmacokinetics of AL-794, a Novel Oral Influenza Endonuclease Inhibitor: Results of an Influenza Human Challenge Study

Autor: Jeysen Yogaratnam, C Andreas Jekle, Thomas N. Kakuda, Julian A. Symons, Pieter Van Remoortere, Sushmita Mukherjee Chanda, Toni Mitchell, Kusum Gupta, Ganesh Balaratnam, Jennifer Rito, Malcolm Boyce, John Fry, Omair Sahgal, Hein Fennema

Publikováno v: The Journal of infectious diseases. 219(2)

Background AL-794 is an orally active prodrug of ALS-033719, which selectively inhibits the endonuclease domain of influenza virus A and B polymerase. Methods In a phase 1, double-blinded, randomized, placebo-controlled study, healthy subjects were i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92e1265ca540d80318bf8ad05ddb95d7
https://pubmed.ncbi.nlm.nih.gov/30053040

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání